±±¾©Ê¯ÓÍ»¯¹¤Ñ§Ôº2026ÄêÑо¿ÉúÕÐÉú½ÓÊÕµ÷¼Á¹«¸æ
²é¿´: 3950  |  »Ø¸´: 50
¡¾½±Àø¡¿ ±¾Ìû±»ÆÀ¼Û44´Î£¬×÷ÕßfzonghuaÔö¼Ó½ð±Ò 35.2 ¸ö
µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû

fzonghua

ÖÁ×ðľ³æ (ÖªÃû×÷¼Ò)


[×ÊÔ´] ÏÖ´úÒ©Îï·ÖÎöµÚ¶þ°æ

INTRODUCTION£º
Modern pharmaceutical analysis encompasses much more than analysis of
active pharmaceutical ingredients (APIs), inert ingredients (excipients), or
formulated drug product (DP). The primary goal of pharmaceutical analysis is
to assure drug quality. It is well known that quality cannot be tested into a product;
however, well-planned testing with suitable methodology and instrumentation
can help build quality into a DP.1 A thorough understanding of interactions of
drug substances with excipients is necessary, especially when residual solvents
(including moisture) are present. It is also essential to understand potential degradation
reactions that may occur in the formulated product under various stress
conditions that might be encountered during storage and in shipment of the final
package. And dissolution tests should correlate well with the bioavailability.
In short, the aim of pharmaceutical analysis is to help build and assure quality
of DPs. Recognition of these principles has encouraged the Food and Drug Administration
(FDA) to issue the new initiative quality by design (QbD) outlined in the
May 2007 FDA report ¡°Pharmaceutical Quality for the 21st Century: A Risk-
Based Approach.¡± The focus of this concept is that quality should be built into
a product by means of a thorough understanding of the product and the process
by which it is developed and manufactured, along with a knowledge of the risks
involved in manufacturing the product and how best to mitigate those risks
through continuous product improvement.
This second edition of Handbook of Modern Pharmaceutical Analysis
addresses QbD and other new developments such as the best ways to monitor
genotoxic impurities (GTIs), separations of chiral compounds, and characterization
and analysis of biopharmaceutical proteins. The first edition published in
2001 has been a popular text among individuals in the pharmaceutical industry
who are involved in drug development and the associated analytical function area.
That book provided a journey through the drug development process, with
emphasis on the role of analytical chemistry. It covered various separation
methods such as thin layer chromatography (TLC), gas chromatography (GC),
high-pressure or high-performance liquid chromatography (HPLC), and capillary
electrophoresis (CE) that are commonly used in the pharmaceutical industry for
the evaluation of a large variety of samples. These methods still remain the methods
of choice for checking purity of new drug candidates, monitoring changes or scaleup
of synthetic procedures, evaluating new formulations, and implementing quality
control/assurance of final DPs. Hyphenated methods that combine a chromatographic
method with spectroscopic methods such as mass spectrometry (MS)
or nuclear magnetic resonance (NMR) have been found useful for characterizing
impurities; these methods are fully covered in that text. The aim of this second edition
is to supplement and complement the first edition and other complementary
volumes on pharmaceutical analysis2¨C4 and to provide a comprehensive text of modern
pharmaceutical analysis that incorporates various relevant requirements and
new initiatives to address DP quality. The key features of the second edition are listed
below:
• Provides the latest analytical technology that allows greater sensitivity and
selectivity.
• Includes methods for monitoring GTIs.
• Highlights implications for pharmaceutical analysis based on the new paradigm,
¡°Quality by Design.¡±
• Covers characterization and analysis of biopharmaceutical proteins, as these
molecules are gaining significance.
• Provides up-to-date information on documentation in light of regulatory
guidance, technology, and industry trends.
This book has been designed to be particularly useful for both novice and
experienced method development chemists in the pharmaceutical industry who
are seeking to update their knowledge. It should continue to serve as a definitive
reference source on pharmaceutical analysis for researchers, analysts, managers,
and pharmaceutical industry regulators.
»Ø¸´´ËÂ¥

» ±¾Ìû¸½¼þ×ÊÔ´Áбí

  • »¶Ó­¼à¶½ºÍ·´À¡£ºÐ¡Ä¾³æ½öÌṩ½»Á÷ƽ̨£¬²»¶Ô¸ÃÄÚÈݸºÔð¡£
    ±¾ÄÚÈÝÓÉÓû§×ÔÖ÷·¢²¼£¬Èç¹ûÆäÄÚÈÝÉæ¼°µ½ÖªÊ¶²úȨÎÊÌ⣬ÆäÔðÈÎÔÚÓÚÓû§±¾ÈË£¬Èç¶Ô°æÈ¨ÓÐÒìÒ飬ÇëÁªÏµÓÊÏ䣺xiaomuchong@tal.com
  • ¸½¼þ 1 : ÏÖ´úÒ©Îï·ÖÎöµÚ¶þ°æ.pdf
  • 2018-12-12 15:02:28, 12.62 M

» ÊÕ¼±¾ÌûµÄÌÔÌûר¼­ÍƼö

sciµÄÖÖÖÖ Ò©Æ·Ñз¢Àà ziliao ÐÂÒ©Ñз¢×¨¼­

» ±¾ÌûÒÑ»ñµÃµÄºì»¨£¨×îÐÂ10¶ä£©

» ²ÂÄãϲ»¶

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

aoÌØÂü

ÖÁ×ðľ³æ (Ö°Òµ×÷¼Ò)


49Â¥2020-06-19 06:47:05
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
²é¿´È«²¿ 51 ¸ö»Ø´ð

apple999

½ð³æ (ÕýʽдÊÖ)


5Â¥2018-12-13 00:09:43
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

zhangh62

ľ³æ (ÖøÃûдÊÖ)


¡ï¡ï¡ï¡ï¡ï ÎåÐǼ¶,ÓÅÐãÍÆ¼ö

·Ç³£¸Ðл¥Ö÷¸ø°³ÃÇ·ÖÏí×ÊÁÏ£¡
9Â¥2018-12-13 09:58:36
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
¼òµ¥»Ø¸´
liushuai192Â¥
2018-12-12 15:14   »Ø¸´  
ÎåÐÇºÃÆÀ  ¶¥Ò»Ï£¬¸Ðл·ÖÏí£¡
1949stone3Â¥
2018-12-12 19:31   »Ø¸´  
ÎåÐÇºÃÆÀ  ¶¥Ò»Ï£¬¸Ðл·ÖÏí£¡
xfiles4Â¥
2018-12-12 21:40   »Ø¸´  
¶¥Ò»Ï£¬¸Ðл·ÖÏí£¡ ·¢×ÔСľ³æAndroid¿Í»§¶Ë
çÞͪ6Â¥
2018-12-13 08:39   »Ø¸´  
ÎåÐÇºÃÆÀ  ¶¥Ò»Ï£¬¸Ðл·ÖÏí£¡
2018-12-13 09:06   »Ø¸´  
ÎåÐÇºÃÆÀ  ¶¥Ò»Ï£¬¸Ðл·ÖÏí£¡
2018-12-13 09:36   »Ø¸´  
ÎåÐÇºÃÆÀ  ¶¥Ò»Ï£¬¸Ðл·ÖÏí£¡
sjshvdc10Â¥
2018-12-13 16:25   »Ø¸´  
ÎåÐÇºÃÆÀ  ¶¥Ò»Ï£¬¸Ðл·ÖÏí£¡
»Û¾²11Â¥
2018-12-13 16:53   »Ø¸´  
ÎåÐÇºÃÆÀ  ¶¥Ò»Ï£¬¸Ðл·ÖÏí£¡
scutcsl12Â¥
2018-12-13 17:16   »Ø¸´  
ÎåÐÇºÃÆÀ  ¶¥Ò»Ï£¬¸Ðл·ÖÏí£¡
wang36913Â¥
2018-12-13 19:41   »Ø¸´  
ÎåÐÇºÃÆÀ  ¶¥Ò»Ï£¬¸Ðл·ÖÏí£¡
xwj00714Â¥
2018-12-13 20:32   »Ø¸´  
ÎåÐÇºÃÆÀ  ¶¥Ò»Ï£¬¸Ðл·ÖÏí£¡
¡î ÎÞÐǼ¶ ¡ï Ò»ÐǼ¶ ¡ï¡ï¡ï ÈýÐǼ¶ ¡ï¡ï¡ï¡ï¡ï ÎåÐǼ¶
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 085701»·¾³¹¤³Ì£¬267Çóµ÷¼Á +11 minht 2026-03-26 11/550 2026-03-27 20:52 by ÈÈÇéɳĮ
[¿¼ÑÐ] 275Çóµ÷¼Á +8 jjjjjjjjjjl 2026-03-27 8/400 2026-03-27 19:40 by yhmsz
[¿¼ÑÐ] 070300Çóµ÷¼Á306·Ö +3 26ÒªÉϰ¶ 2026-03-27 3/150 2026-03-27 17:57 by arrow8852
[¿¼ÑÐ] 266Çóµ÷¼Á +11 ÑôÑôÍÛÈû 2026-03-27 12/600 2026-03-27 17:56 by yu221
[¿¼ÑÐ] Ò»Ö¾Ô¸ÄÏʦ´ó0703»¯Ñ§ 275Çóµ÷¼Á +4 RipcordÉϰ¶ 2026-03-27 4/200 2026-03-27 17:00 by zhyzzh
[¿¼ÑÐ] 322Çóµ÷¼Á +4 ÎÒÕæµÄºÜÏëѧϰ 2026-03-23 4/200 2026-03-27 13:51 by ÑîÑîÑî×Ï
[¿¼ÑÐ] 316Çóµ÷¼Á +5 Pigcasso 2026-03-24 5/250 2026-03-27 12:10 by zhshch
[¿¼ÑÐ] 286Çóµ÷¼Á +4 lim0922 2026-03-26 4/200 2026-03-27 10:28 by guoweigw
[¿¼ÑÐ] Ò»Ö¾Ô¸ÉÂʦ´óÉúÎïѧ071000£¬298·Ö£¬Çóµ÷¼Á +5 SYA£¡ 2026-03-23 5/250 2026-03-27 09:29 by ²»³Ôô~µÄ؈
[¿¼ÑÐ] 333Çóµ÷¼Á +6 wfh030413@ 2026-03-23 6/300 2026-03-26 22:45 by ѧԱ8dgXkO
[¿¼ÑÐ] Ò»Ö¾Ô¸»ªÀí£¬ÊýÒ»Ó¢Ò»285ÇóAÇøµ÷¼Á +8 AZMK 2026-03-25 10/500 2026-03-26 22:37 by ѧԱ8dgXkO
[¿¼ÑÐ] 297Çóµ÷¼Á +6 ÌïºéÓÐ 2026-03-26 6/300 2026-03-26 15:55 by ²»³Ôô~µÄ؈
[¿¼ÑÐ] »·¾³×¨Ë¶324·ÖÇóµ÷¼ÁÍÆ¼ö +5 ÐùСÄþ¡ª¡ª 2026-03-26 5/250 2026-03-26 12:05 by i_cooler
[¿¼ÑÐ] 291 Çóµ÷¼Á +7 »¯¹¤2026½ì±ÏÒµÉ 2026-03-21 8/400 2026-03-26 11:25 by AlenQIN.
[¿¼²©] 26É격×Ô¼ö +3 whh869393 2026-03-24 3/150 2026-03-24 09:55 by 21018060
[¿¼ÑÐ] Ò»Ö¾Ô¸¹ú¿Æ¹ý³ÌËù081700£¬274Çóµ÷¼Á +3 ÈýË®ÑÐ0Ë®Á¢·½ 2026-03-23 3/150 2026-03-23 23:11 by MajorWen
[¿¼ÑÐ] ÉúÎïѧһ־Ը985£¬·ÖÊý349Çóµ÷¼Á +6 zxts12 2026-03-21 9/450 2026-03-23 18:37 by macy2011
[¿¼ÑÐ] Ò»Ö¾Ô¸¶«»ª´óѧ¿ØÖÆÑ§Ë¶320Çóµ÷¼Á +3 Grand777 2026-03-21 3/150 2026-03-21 19:23 by ¼òÖ®-
[¿¼ÑÐ] Ò»Ö¾Ô¸ÄÏ´ó£¬0703»¯Ñ§£¬·ÖÊý336£¬Çóµ÷¼Á +3 ÊÕµ½VS 2026-03-21 3/150 2026-03-21 18:42 by ѧԱ8dgXkO
[¿¼ÑÐ] 0805²ÄÁÏ320Çóµ÷¼Á +3 ÉÎïÓï 2026-03-20 3/150 2026-03-21 15:46 by Î޼ʵIJÝÔ­
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û